Zealand Pharma Opens Research Hub in Cambridge, Massachusetts to Enhance Drug Discovery

Zealand Pharma A/S has announced the establishment of a new research hub in Cambridge, Massachusetts, aimed at expanding its drug discovery capabilities. The facility is set to become operational in September 2026 and will serve as the company’s primary U.S. address. The hub will focus on AI-driven drug discovery and next-generation molecule creation, enhancing Zealand's research platform and strengthening partnerships in the biotech ecosystem.

Published Mar 26, 2026

Zealand Pharma A/S is establishing a research hub in Cambridge, Massachusetts, expected to be operational by September 2026. This site will serve as Zealand's primary U.S. address and aims to enhance its global research capabilities in obesity and metabolic health.

AI-curated by Theia

The hub will utilize AI-driven drug discovery and advanced automation to accelerate the development of innovative medicines. It will include research laboratories, office space, and collaborative areas, further integrating Zealand's research efforts within the U.S. biotech ecosystem.